Cambridge Healthtech Institute’s 21st Annual

Engineering Antibodies

May 6-7, 2020

The field of protein engineering is at an exciting point in its development, with new generations of therapeutic antibodies now progressing through development and into the market, great advances in protein science and discovery technology, and a body of clinical evidence that can be used to inform the development of safe, highly effective therapies for unmet medical needs. The PEGS Engineering Antibodies conference explores case examples of the most significant emerging discovery and informatics technologies used by protein engineers working at the discovery and design stages to quickly and efficiently craft biotherapeutics directed at the most elusive targets and biological functions.

Preliminary Agenda

APPLICATIONS OF MACHINE LEARNING IN BIOTHERAPEUTIC R&D

Applying Machine Learning to Improve Protein Expression and Solubility

Erik Vernet, PhD, Director, Protein Engineering, Novo Nordisk Research Center Seattle

Design of Proteins and Antibodies Using Machine Learning

Philip Kim, PhD, Associate Professor, Molecular Genetics, University of Toronto

KEYNOTE PRESENTATION: Machine Learning-Based Antibody Discovery

David Gifford, PhD, Professor, Computer Science and Biological Engineering, MIT

IMPROVING TARGETING SPECIFICITY

Design of Exquisite Binding Specificity

Shohei Koide, PhD, Professor, Biochemistry and Molecular Pharmacology, NYU

A Novel Mammalian Display Platform for the Engineering of Highly Specific T Cell Receptors

Rodrigo Vazquez-Lombardi, PhD, Postdoctoral Fellow, Biosystems Science and Engineering, ETH Zurich, Switzerland

Engineering Acidic pH Selective mAbs Targeting VISTA

Julie Su, PhD, Senior Research Investigator, Molecular Discovery Technologies, Bristol Myers Squibb

SUBCELLULAR AND INTRACELLULAR TARGETING

Subcellular Trafficking Pathways as Targets for the Design of Therapies for Autoimmunity and Cancer

Sally Ward, PhD, Professor, Molecular Immunology, University of Southampton, United Kingdom

Developing Therapeutics for Intracellular Targets

Francois-Thomas Michaud, PhD, CEO, Feldan Therapeutics

OVERCOMING LIABILITIES

Presentation of Non-Germline Residues and Clinical Consequences: A Case Study

Nicoletta Bivi, PhD, Director, Assay Development, Immunogenicity and Immunoassays, Laboratory for Experimental Medicine (LEM), Eli Lilly and Company

Molecular Design Intent in Early Drug Discovery

Carlos R. Reis, PhD, Team Leader, Molecular Design and Engineering, GlaxoSmithKline, United Kingdom

CHALLENGES AND SOLUTIONS

Next-Generation Technologies for Antibody Library Design and Screening

Brandon DeKosky, PhD, Assistant Professor, Chemical Engineering, University of Kansas

A High-Throughput Production Workflow for Complex Format Therapeutic Molecules

Avinash Gill, PhD, Senior Scientific Manager, Genentech

LUNCHEON PRESENTATION I: Lessons in Generating Monoclonal Antibodies against Multipass Membrane Proteins

Ross Chambers, PhD, Vice President, Antibody Discovery, Integral Molecular

Antibody Protein Sequencing with Mass Spectrometry

Anthony Stajduhar, Business Development Manager, Sales, Rapid Novor, Inc.

* The program is subject to change without notice, due to unforeseen reason.